Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Philip Home , Stuart Pocock , Henning Beck‐Nielsen +6 more 2009 The Lancet 1385 citations